Abstract
Bipolar, epilepsy and migraine disorders are frequently reported as co-morbid conditions. In this review article we highlight some of the similarities between these disorders, exploring at various levels including cellular, structural and phenotypic changes. Clinical observations suggest considerable overlap with a number of common neurobiological features. Nonetheless, the courses of development of each disorder remain to be elucidated such that there is much room for further research into their precise underlying mechanisms. A better understanding of the neurobiology of these disorders will help to improve current treatments, particularly when there is co-morbidity and presence of treatment resistant and complex cases.
Keywords: Bipolar disorder, comorbidity, depressive disorders, epilepsy, migraine, psychopharmacology.
Current Psychopharmacology
Title:Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Volume: 2
Author(s): Jonathon Holland, Mark Agius and Rashid Zaman
Affiliation:
Keywords: Bipolar disorder, comorbidity, depressive disorders, epilepsy, migraine, psychopharmacology.
Abstract: Bipolar, epilepsy and migraine disorders are frequently reported as co-morbid conditions. In this review article we highlight some of the similarities between these disorders, exploring at various levels including cellular, structural and phenotypic changes. Clinical observations suggest considerable overlap with a number of common neurobiological features. Nonetheless, the courses of development of each disorder remain to be elucidated such that there is much room for further research into their precise underlying mechanisms. A better understanding of the neurobiology of these disorders will help to improve current treatments, particularly when there is co-morbidity and presence of treatment resistant and complex cases.
Export Options
About this article
Cite this article as:
Holland Jonathon, Agius Mark and Zaman Rashid, Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?, Current Psychopharmacology 2013; 2 (2) . https://dx.doi.org/10.2174/2211556011302020001
DOI https://dx.doi.org/10.2174/2211556011302020001 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Brain Serotonin, Psychoactive Drugs, and Effects on Reproduction
Central Nervous System Agents in Medicinal Chemistry Phytol a Natural Diterpenoid with Pharmacological Applications on Central Nervous System: A Review
Recent Patents on Biotechnology Adult Neurogenesis: Can Analysis of Cell Cycle Proteins Move Us “Beyond BrdU”?
Current Pharmaceutical Biotechnology Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective
Current Neuropharmacology High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Editorial [Hot Topic: Peripheral Proteins as Drug Targets (Guest Editor: Robert V. Stahelin) ]
Current Drug Targets Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues – Volume II)
Current Drug Metabolism Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Fad Diets: Dietary Dilemmas, Predicaments, and Recommendations for its Use
Current Nutrition & Food Science Nanotechnology and Drug Delivery: Getting There is Only Half of the Challenge! (Commentary)
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Sodium Channel Blocking Activity and In-vivo Testing of New Phenylimidazole Derivatives
Letters in Drug Design & Discovery Drugs from the Sea: Conopeptides as Potential Therapeutics
Current Medicinal Chemistry Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews